A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

Add-on therapy and substitution monotherapy are both effective second-line treatments for women with idiopathic generalized epilepsy.

Counties designated as maternity care deserts face significantly higher maternal mortality rates than those with full access ...

Before blaming your campaign, check your tracking. These seven conversion pitfalls in Google Ads can quietly wreck your ...

Within PEDSnet data, from 2010 to 2023, conditions with the largest increases were major depression (RR 3.30), sleep apnea ...

Erenumab is not associated with significant reductions in weekly attacks in patients with chronic cluster headache vs placebo ...

Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in ...

By adopting FDA-endorsed primary endpoints that are easier to achieve, Dimerix has bolstered the chances of its phase III ...

They were randomised in a 2:1 ratio to receive either mifepristone (300–900 mg daily) or placebo for 24 weeks. Randomisation ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This situation generates substantial inefficiencies with many scanners being ...